1. Hong Kong Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
HUTCHMED (China) Limited

HUTCHMED (China) Limited

14.24
USD
-0.50
(-3.42%)
2.34BMarket Cap
Mar 04Next Earn
HUTCHMED (China) Limited
LSE:0J7G
(London Stock Exchange)

Recent

price

14.24

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
USD
1.27
1.56
0.21
0.43
0.81
1.59
1.77
1.91
1.57
1.5
1.59
2.19
2.46
4.81
3.59
3.12
- -
Revenue per Share
-0.06
0.01
0.03
0.06
-0.07
0.07
0.1
-0.21
-0.55
-0.78
-0.88
-1.2
-2.08
0.58
0.22
2.6
- -
Basic EPS, GAAP
-0.27
0.02
-0.11
0.02
0.04
-0.11
-0.11
-0.11
-0.29
-0.66
-0.59
-1.36
-1.76
1.07
-0.1
-0.5
- -
Free Cash Flow per Basic Share
- -
- -
0.01
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.56
0.61
6.62
8.33
3.6
0.67
1.48
3.39
2.85
2.11
3.25
5.62
3.52
4.18
4.34
7.03
7.03
Book Value per Share
0.39
0.39
6.58
8.29
3.22
0.64
1.45
3.36
2.82
2.08
3.22
5.6
3.52
4.18
4.32
7.01
7.01
Tangible Book Value per Share
106
106
106
107
108
112
122
126
136
136
143
162
174
174
175
176
173
Basic Weighted Avg Shares
135
165
22
46
87
178
216
241
214
205
228
356
426
838
630
549
- -
Sales/Revenue/Turnover
-1.93
4
-77.95
-2.28
-20.91
-5.48
-21.61
-22.1
-43.27
-71.45
-86.27
-92.1
-95.27
2.57
-6.44
-6.51
- -
Operating Margin (%)
5
5
2
1
1
2
2
3
4
5
6
7
9
8
12
13
- -
Depreciation Expense
-7
1
4
6
-7
8
12
-27
-75
-106
-126
-195
-361
101
38
457
- -
Net Income, GAAP
- -
50.48
9.4
10.43
- -
- -
- -
- -
- -
- -
- -
- -
- -
7.73
- -
12.76
- -
Effective Tax Rate (%)
-5.1
0.43
16.27
12.87
-8.37
4.49
5.41
-11.08
-34.94
-51.75
-55.15
-54.66
-84.62
12.03
5.99
83.3
- -
Profit Margin (%)
40
52
9
-11
15
8
72
328
285
204
372
900
486
694
690
1,252
1,252
Working Capital
- -
- -
27
- -
27
27
27
- -
27
30
33
7
23
51
64
70
70
LT Debt
69
77
82
105
98
102
204
485
412
313
519
1,040
637
743
772
1,251
1,251
Total Equity
- -
3.31
10.34
7.49
- -
- -
- -
- -
- -
- -
- -
- -
- -
1.94
- -
34.67
- -
Return on Invested Capital (%)
- -
- -
3.84
4.12
- -
- -
- -
- -
- -
- -
- -
- -
- -
13.55
- -
41.49
- -
Return on Capital (%)
-10.94
1.14
5.38
7.42
-11.41
13.05
8.74
-8.28
-17.59
-31.32
-32.57
-26.46
-45.18
15.03
5.06
45.74
- -
Return on Common Equity (%)

Capital Structure

USD

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
26
- -
28
LT Borrowings
59
93
68
LT Finance Leases
4
- -
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
175
176
176
Market Capitalization
2,527
2,669
2,340

Working Capital

USD

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
1,067
1,592
1,567
Cash, Cash Equivalents & STI
836
- -
1,367
Accounts Receivable, Net
156
147
127
Inventories
50
- -
41
Total Current Liabilities
377
342
316
Payables & Accruals
- -
- -
- -
ST Debt
26
- -
28
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
40.82%
28.85%
62.11%
Free Cash Flow
65.28%
68.03%
409.32%
Net Income, GAAP
101.86%
212.15%
1,111.03%
Sales/Revenue/Turnover
16.33%
26.94%
-12.96%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

USD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
838
2024
- -
- -
630
2025
- -
- -
549

Semi-annual Earnings Per Share

USD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.58
2024
- -
- -
0.22
2025
- -
- -
2.6

Semi-annual Dividends Per Share

USD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

Company News

Company News APIChatGPT

  • globenewswire.com

    HUTCHMED Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside China

  • seekingalpha.com

    Braveheart Bio: In Non-Obstructive HCM, The Therapeutic Window Is The Product

  • defenseworld.net

    HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Stock Has Consensus Price Target of $14.87 According to Analysts

  • 247wallst.com

    ADP Warns of Cooling Labor Market While Its Own Business Feels the Chill

  • seekingalpha.com

    Lexicon Pharmaceuticals: Upgrading On Sotagliflozin HCM Data In Q1 '27 And More

  • reuters.com

    AstraZeneca files US FDA application for HUTCHMED lung cancer drug combination

  • globenewswire.com

    HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer

  • globenewswire.com

    HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors

  • globenewswire.com

    HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2026

  • gurufocus.com

    New 3Sixty Insights Analysis Reinforces the Importance of Insperity's HRScale Service-Enabled HR Solution

  • marketbeat.com

    Lexicon Completes SONATA-HCM Enrollment, Eyes 2027 Sotagliflozin Data

  • gurufocus.com

    Workday Named a Leader in Inaugural 2026 Gartner® Magic Quadrant™ for Workforce Management Technology

  • marketbeat.com

    HUTCHMED Lands GSK Deal Worth Up to $1.3B for KRAS-EGFR Cancer Therapy

  • seekingalpha.com

    HUTCHMED (China) Limited (HCM) Discusses Strategic Partnership With GSK and Licensing of Oncology Asset A830 Transcript

  • proactiveinvestors.co.uk

    Panmure and Cavendish reiterate buy on Hutchmed after GSK deal

  • proactiveinvestors.co.uk

    HUTCHMED shares jump 17% on US$1.3 billion GSK cancer drug deal

  • reuters.com

    HUTCHMED (China) signs licensing deal with GSK for experimental solid tumour drug

  • globenewswire.com

    HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy

  • gurufocus.com

    Workday Named a Leader in 2026 Gartner® Magic Quadrant™ for Cloud HCM Suites for 1,000+ Employee Enterprises for Eleventh Consecutive Year

  • globenewswire.com

    HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit of ORPATHYS® Plus TAGRISSO® in Treatment-Naïve Patients with MET-Overexpressing EGFR-mutated Lung Cancer in China